Literature DB >> 34598429

Antiviral therapy and immunotherapy of COVID-19.

C Crespillo, S Moreno1.   

Abstract

The pharmacological treatment of COVID-19 has evolved in the months since the description of the disease. Published observational studies and, above all, clinical trials have highlighted drugs that are useful as well as ruled out any benefit from other drugs used at the beginning of the pandemic. The pathogenesis of the disease has suggested that patients may benefit from the administration of both antivirals, mainly in the earliest stages, and anti-inflammatory/immunomodulatory medications in more advanced stages. We present a short review of the drugs used and under investigation for the treatment of COVID-19.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34598429      PMCID: PMC8683015          DOI: 10.37201/req/s01.17.2021

Source DB:  PubMed          Journal:  Rev Esp Quimioter        ISSN: 0214-3429            Impact factor:   1.553


  16 in total

1.  Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets.

Authors:  Robert M Cox; Josef D Wolf; Richard K Plemper
Journal:  Nat Microbiol       Date:  2020-12-03       Impact factor: 17.745

2.  Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care.

Authors:  Susan A Olender; Katherine K Perez; Alan S Go; Bindu Balani; Eboni G Price-Haywood; Nirav S Shah; Su Wang; Theresa L Walunas; Shobha Swaminathan; Jihad Slim; BumSik Chin; Stéphane De Wit; Shamim M Ali; Alex Soriano Viladomiu; Philip Robinson; Robert L Gottlieb; Tak Yin Owen Tsang; I-Heng Lee; Hao Hu; Richard H Haubrich; Anand P Chokkalingam; Lanjia Lin; Lijie Zhong; B Nebiyou Bekele; Robertino Mera-Giler; Chloé Phulpin; Holly Edgar; Joel Gallant; Helena Diaz-Cuervo; Lindsey E Smith; Anu O Osinusi; Diana M Brainard; Jose I Bernardino
Journal:  Clin Infect Dis       Date:  2021-12-06       Impact factor: 9.079

3.  Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.

Authors: 
Journal:  Lancet       Date:  2021-03-04       Impact factor: 79.321

4.  Efficacy and safety of lopinavir-ritonavir in COVID-19: A systematic review of randomized controlled trials.

Authors:  Tejas K Patel; Parvati B Patel; Manish Barvaliya; Manoj Kumar Saurabh; Hira Lal Bhalla; Prem Parkash Khosla
Journal:  J Infect Public Health       Date:  2021-04-20       Impact factor: 3.718

5.  Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.

Authors:  Hongchao Pan; Richard Peto; Ana-Maria Henao-Restrepo; Marie-Pierre Preziosi; Vasee Sathiyamoorthy; Quarraisha Abdool Karim; Marissa M Alejandria; César Hernández García; Marie-Paule Kieny; Reza Malekzadeh; Srinivas Murthy; K Srinath Reddy; Mirta Roses Periago; Pierre Abi Hanna; Florence Ader; Abdullah M Al-Bader; Almonther Alhasawi; Emma Allum; Athari Alotaibi; Carlos A Alvarez-Moreno; Sheila Appadoo; Abdullah Asiri; Pål Aukrust; Andreas Barratt-Due; Samir Bellani; Mattia Branca; Heike B C Cappel-Porter; Nery Cerrato; Ting S Chow; Najada Como; Joe Eustace; Patricia J García; Sheela Godbole; Eduardo Gotuzzo; Laimonas Griskevicius; Rasha Hamra; Mariam Hassan; Mohamed Hassany; David Hutton; Irmansyah Irmansyah; Ligita Jancoriene; Jana Kirwan; Suresh Kumar; Peter Lennon; Gustavo Lopardo; Patrick Lydon; Nicola Magrini; Teresa Maguire; Suzana Manevska; Oriol Manuel; Sibylle McGinty; Marco T Medina; María L Mesa Rubio; Maria C Miranda-Montoya; Jeremy Nel; Estevao P Nunes; Markus Perola; Antonio Portolés; Menaldi R Rasmin; Aun Raza; Helen Rees; Paula P S Reges; Chris A Rogers; Kolawole Salami; Marina I Salvadori; Narvina Sinani; Jonathan A C Sterne; Milena Stevanovikj; Evelina Tacconelli; Kari A O Tikkinen; Sven Trelle; Hala Zaid; John-Arne Røttingen; Soumya Swaminathan
Journal:  N Engl J Med       Date:  2020-12-02       Impact factor: 91.245

6.  Decreased Mortality in Coronavirus Disease 2019 Patients Treated With Tocilizumab: A Rapid Systematic Review and Meta-analysis of Observational Studies.

Authors:  Jishnu Malgie; Jan W Schoones; Bart G Pijls
Journal:  Clin Infect Dis       Date:  2021-06-01       Impact factor: 9.079

7.  Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial.

Authors:  Jurjan Aman; Erik Duijvelaar; Liza Botros; Azar Kianzad; Job R Schippers; Patrick J Smeele; Sara Azhang; Imke H Bartelink; Ahmed A Bayoumy; Pierre M Bet; Wim Boersma; Peter I Bonta; Karin A T Boomars; Lieuwe D J Bos; Job J M H van Bragt; Gert-Jan Braunstahl; Lucas R Celant; Katrien A B Eger; J J Miranda Geelhoed; Yurika L E van Glabbeek; Hans P Grotjohan; Laura A Hagens; Chris M Happe; Boaz D Hazes; Leo M A Heunks; Michel van den Heuvel; Wouter Hoefsloot; Rianne J A Hoek; Romke Hoekstra; Herman M A Hofstee; Nicole P Juffermans; E Marleen Kemper; Renate Kos; Peter W A Kunst; Ariana Lammers; Ivo van der Lee; E Laurien van der Lee; Anke-Hilse Maitland-van der Zee; Pearl F M Mau Asam; Adinda Mieras; Mirte Muller; Liesbeth Neefjes; Esther J Nossent; Laurien M A Oswald; Maria J Overbeek; Carolina Pamplona; Nienke Paternotte; Niels Pronk; Michiel A de Raaf; Bas F M van Raaij; Merlijn Reijrink; Marcus J Schultz; Ary Serpa Neto; Elise M Slob; Frank W J M Smeenk; Marry R Smit; A Josien Smits; Janneke E Stalenhoef; Pieter R Tuinman; Arthur L E M Vanhove; Jessie N Wessels; Jessie C C van Wezenbeek; Anton Vonk Noordegraaf; Frances S de Man; Harm J Bogaard
Journal:  Lancet Respir Med       Date:  2021-06-17       Impact factor: 30.700

8.  Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.

Authors:  Bhagteshwar Singh; Hannah Ryan; Tamara Kredo; Marty Chaplin; Tom Fletcher
Journal:  Cochrane Database Syst Rev       Date:  2021-02-12

9.  Dexamethasone in Hospitalized Patients with Covid-19.

Authors:  Peter Horby; Wei Shen Lim; Jonathan R Emberson; Marion Mafham; Jennifer L Bell; Louise Linsell; Natalie Staplin; Christopher Brightling; Andrew Ustianowski; Einas Elmahi; Benjamin Prudon; Christopher Green; Timothy Felton; David Chadwick; Kanchan Rege; Christopher Fegan; Lucy C Chappell; Saul N Faust; Thomas Jaki; Katie Jeffery; Alan Montgomery; Kathryn Rowan; Edmund Juszczak; J Kenneth Baillie; Richard Haynes; Martin J Landray
Journal:  N Engl J Med       Date:  2020-07-17       Impact factor: 91.245

10.  Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.

Authors:  Andre C Kalil; Thomas F Patterson; Aneesh K Mehta; Kay M Tomashek; Cameron R Wolfe; Varduhi Ghazaryan; Vincent C Marconi; Guillermo M Ruiz-Palacios; Lanny Hsieh; Susan Kline; Victor Tapson; Nicole M Iovine; Mamta K Jain; Daniel A Sweeney; Hana M El Sahly; Angela R Branche; Justino Regalado Pineda; David C Lye; Uriel Sandkovsky; Anne F Luetkemeyer; Stuart H Cohen; Robert W Finberg; Patrick E H Jackson; Babafemi Taiwo; Catharine I Paules; Henry Arguinchona; Nathaniel Erdmann; Neera Ahuja; Maria Frank; Myoung-Don Oh; Eu-Suk Kim; Seow Y Tan; Richard A Mularski; Henrik Nielsen; Philip O Ponce; Barbara S Taylor; LuAnn Larson; Nadine G Rouphael; Youssef Saklawi; Valeria D Cantos; Emily R Ko; John J Engemann; Alpesh N Amin; Miki Watanabe; Joanne Billings; Marie-Carmelle Elie; Richard T Davey; Timothy H Burgess; Jennifer Ferreira; Michelle Green; Mat Makowski; Anabela Cardoso; Stephanie de Bono; Tyler Bonnett; Michael Proschan; Gregory A Deye; Walla Dempsey; Seema U Nayak; Lori E Dodd; John H Beigel
Journal:  N Engl J Med       Date:  2020-12-11       Impact factor: 176.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.